DSM Biologics and Upfront to Develop A Fully Disposable Chromatography System Optimized for High Yield Cell Line Production

DSM Biologics, a business unit of DSM Pharmaceutical Products, and
Upfront Chromatography A/S, a leading developer of customized
industrial-scale separation services, today announced the
collaboration between the two companies to optimize Upfront´s new

fully disposable chromatography system for use with DSM´s proprietary
manufacturing technology. The fully integrated disposable
chromatography system will offer biopharmaceutical manufacturers
significant efficiency and productivity benefits and is expected to be
available for commercial use by the summer of 2008.

The combination of Upfront´s unique disposable chromatography
system and DSM´s proprietary manufacturing technology will deliver a
flexible, easy-to-use and high capacity bioprocessing platform that
can be scaled from 0.1L to 100L for commercial manufacture and
recovery of a range of biopharmaceuticals, including monoclonal
antibodies.

Upfront´s proprietary cGMP-manufactured adsorbents, fluid
processing platforms and ligand chemistries enable the production of a
fully disposable chromatography system for bioprocessing: bringing
together the excellent performance of affinity chromatography with the
safety and cost-effectiveness of disposable components.

"Industrial chromatography systems were for many years thought to
have no fully disposable solution." commented Karen King, President

DSM Biologics. "Together with Upfront, we will be developing a
combination of a unique disposable module and a high yield cell line
that will for the first time enable the creation of a fully
integrated, disposable biologic manufacturing process."

Michael Bennett, CEO of Upfront said: "The biopharmaceutical
industry has been seeking fully disposable chromatography systems over
recent years. Our technology offers manufacturers all the productivity
benefits they expect from industrial-scale chromatography systems and
with DSM Biologics we have the perfect partner to drive this
combination of disposable systems and high yield cell lines to
market."

About disposable chromatography

Upfront´s integrated disposable chromatography system is based on
its proprietary Rhobust(TM) universal processing platform. Rhobust has
been implemented in a range of industrial settings for
commercial-scale recovery and purification of functional biomolecules

including monoclonal antibodies, direct from crude feedstocks. A key
feature of Rhobust, and in particular the disposable system, is that
it does not generate pressure during operation: enabling construction
of cost-effective, single-use columns from plastic. The combined
advantages of disposability and crude feedstock processing has
delivered a single high-yielding system which eliminates the
requirement for both cleaning validation and further clarification
steps, such as filtration and centrifugation.

About Upfront Chromatography

Upfront Chromatography A/S develops and manufactures innovative
products and technologies for extraction and recovery of
biotherapeutics, functional biomolecules, macromolecular complexes

and even living cells, directly from bioreactors and industrial
side-streams.

For customised separation services, Upfront offers access to its
proprietary universal process platforms combined with extensive
technical and regulatory support. From a feasibility study to
commissioning of the final installation, Upfront works with its
customers to develop adsorbents, ligand chemistry, columns and other
hardware to optimise process performance.

Upfront´s research, development and ISO9001-compliant
manufacturing facility is situated in Copenhagen, Denmark. Please
visit: www.upfront-dk.com

About DSM Biologics

DSM Biologics, a business unit of DSM Pharmaceutical Products, is
a global provider of manufacturing technology & services to the
biopharmaceutical industry. In addition to offering world-class
biopharmaceutical manufacturing services, DSM Biologics has
co-exclusive rights, along with Dutch biotech company Crucell N.V., to
license the high-producing PER.C6(R) human cell line as a production
platform for recombinant proteins and monoclonal antibodies. The
combination of the PER.C6(R) human cell line and DSM´s manufacturing
services provides companies with a turn-key biologic manufacturing
solution reducing cost, risk and time to market.

DSM - the Life Sciences and Materials Sciences Company

DSM creates innovative products and services in Life Sciences and
Materials Sciences that contribute to the quality of life. DSM´s
products and services are used globally in a wide range of markets and
applications, supporting a healthier, more sustainable and more
enjoyable way of life. End markets include human and animal nutrition
and health, personal care, pharmaceuticals, automotive, coatings and
paint, electrics and electronics, life protection and housing. DSM has
annual sales of almost EUR 8.8 billion and employs some 23,000 people
worldwide. The company is headquartered in the Netherlands, with
locations on five continents. DSM is listed on Euronext Amsterdam.